Ruth Voor

Upon graduating from the United States Naval Academy in 1983, Ruth received her commission as an officer in the US Naval Supply Corps and served for 6 years.  During her tenure as an officer, Ruth received numerous leadership awards including Naval Achievement, Naval Commendation medals and Service Warfare Officer Qualification.  She joined Johnson and Johnson in 1989 and was recognized for her success by being promoted from night shift production supervisor to plant manager within 3 years.   Ruth then moved into research and development roles of increasing responsibility and culminated this phase of her career by successfully bringing the first drug eluting stent to market: CYHPER™.  Following this blockbuster global launch, Ruth transferred to strategic portfolio and product marketing.  Here she was responsible for sustaining the success of CYPHER™ and orchestrated the global launch of 2nd and 3rd generation drug eluting stents.  She also expanded the strategic focus of her company by identifying and championing other percutaneous interventional opportunities: mitral and aortic valve repair and replacement, vein graft stenting, and vulnerable plaque diagnosis with local drug delivery platform design.  Ruth now is the President and CEO of Vivorte, Inc.; an orthopedic device commercialization company, focused on bringing innovative orthopedic technologies to market.

Vivorte’s mission is to identify, develop, commercialize & out-license orthopedic devices which address a clear unmet need in markets exceeding $1Billion. We currently have 2 products: a minimally invasive implantable device designed to reduce hip fractures and save lives, and a synthetic/biologic bone void filler which is both strong and remodels quickly.

A patent has been issued for both products and the unique bone void filler received FDA clearance.  Vivorte successfully launched the bone void filler last year for trauma and is working to expand clinical indications.